Result of AGM

Summary by AI BETAClose X

OptiBiotix Health plc announced that all resolutions were duly passed at its Annual General Meeting. The company, listed on AIM as OPTI and OTCQB as OPTBF, is a life sciences business focused on developing products for hunger reduction, microbiome enhancement, and sugar substitutes. The full voting results will be made available on the company's website.

Disclaimer*

OptiBiotix Health PLC
23 June 2026
 

 

 

OptiBiotix Health plc

 

("OptiBiotix" or the "Company" or the "Group")

 

Result of AGM

 

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitute, announces that at its Annual General Meeting held earlier today, all resolutions were duly passed.

 

The full voting results will be available on the website in due course here: https://optibiotix.com/shareholder-information

 

 

The Directors of the Company are responsible for the release of this announcement.

 

 

For further information, please contact: OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

 

Stephen O'Hara, Chief Executive


 


Cairn Financial Advisers LLP (NOMAD and Broker)

Tel: 020 7213 0880

Liam Murray / Ludovico Lazzaretti / James Western

 


About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), OptiBiotix Health has developed a range of technologies and commercialised products which modulate the human microbiome to help prevent and manage human disease.  Since the Group's inception it has created a wide range of microbiome-based ingredients and products including prebiotic products like SlimBiome®, WellBiome®, SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc (OPTI) business, but also skincare through its holdings in SkinBioTherapeutics PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies create a diverse portfolio technologies and products in an emerging area of healthcare that is of growing interest in consumer markets throughout the world.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings